mCRPC: early PRO data favor abiraterone in AQUARiUS

  • Thiery-Vuillemin A & al.
  • ESMO Open
  • 1 Jan 2018

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Initial analysis of ongoing AQUARiUS trial indicates abiraterone acetate plus prednisone (AAP) provides significant benefit in cognitive outcome and fatigue in patients with metastatic castration-resistant prostate cancer (mCRPC) vs enzalutamide.
  • No significant difference was observed in pain outcome.

Why this matters

  • Both treatments improved survival of mCRPC; differences in patient-reported outcomes (PROs) may help physicians choose the most appropriate treatment in specific patients.
  • Final data are needed to confirm initial findings.

Study design

  • AQUARiUS is an ongoing, 2-cohort, phase 4 European study.
  • 105 patients were evaluated at 3 months: 46 patients were treated with AAP and 59 received enzalutamide.
  • Funding: Janssen Pharmaceutica N.V.

Key results

  • At 3 months, AAP vs enzalutamide significantly improved:
    • Cognitive impairment (Functional Assessment of Cancer Therapy-Cognitive Function): mean difference (MD), 6.64; P=.025.
    • Cognitive functioning (Quality of Life Questionnaire-C30 [QLQ-C30]): MD, 11.82; P=.035.
    • Usual level of fatigue (Brief Fatigue Inventory-Short Form [BFI-SF]): MD, −1.41; P=.038.
    • Fatigue interference (BFI-SF): MD, −1.20; P=.036.
    • Current fatigue (BFI-SF): MD, −1.41; P=.017.
    • Worse level of fatigue (BFI-SF): MD, −1.63; P=.019.
    • Fatigue (QLQ-C30): MD, −16.20; P=.009.
    • Pain (QLQ-C30): MD, −13.59; P=.017.
  • No significant differences between cohorts were observed for pain (Brief Pain Inventory-Short Form) at any time-point.

Limitations

  • Observational study.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit